
To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in treating patients with IPF. In a phase IIb randomized, double-blind, placebo-controlled trial, patients with IPF were randomized 1:1 to once-weekly subcutaneous BG00011 56 mg or placebo. One hundred six patients were randomized and received at least one dose of BG00011 or placebo. The results do not support the continued clinical development of BG00011. Further research is warranted to identify new treatment strategies that modify inflammatory and fibrotic pathways in IPF.
Like
Save
Share